Company Filing History:
Years Active: 2019-2025
Title: John Öhd: Innovator in Liver Cancer Therapy
Introduction
John Öhd is a notable inventor based in Huddinge, Sweden. He has made significant contributions to the field of cancer treatment, particularly focusing on liver cancer therapies. With a total of 3 patents to his name, Öhd's work is paving the way for innovative treatment options.
Latest Patents
Öhd's latest patents include a combination therapy involving sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine. This combination therapy demonstrates surprising utility in treating liver cancer and liver metastasis. The formula includes variables where Y represents a straight or branched chain alkyl, X can be H, halo, C-C cycloalkyl, or C-C alkyl, and Z can be H or fluoro, or a pharmaceutically acceptable salt thereof.
Career Highlights
John Öhd is currently associated with Medivir Aktiebolag, a company known for its focus on innovative therapies. His work at Medivir has been instrumental in advancing treatment options for patients suffering from liver cancer.
Collaborations
Öhd collaborates with notable colleagues such as Mark Albertella and Anders Eneroth, contributing to a dynamic research environment that fosters innovation.
Conclusion
John Öhd's contributions to liver cancer therapy through his innovative patents and collaborations highlight his role as a key figure in the field of medical research. His work continues to inspire advancements in cancer treatment.